We go over your health history, the medications you take, your weight-related concerns, and whether you meet the criteria to begin
7 The evolving public perception of obesity and food addiction As the success of GLP-1RAs in treating overweight and obesity rises, it prompts reflection on how these pharmacological advances could reshape both public and professional perspectives
In a phase II study, MariTide demonstrated weight loss of up to approximately 20% in people living with obesity without T2DM, compared with 2.6% in the placebo group and up to approximately 17% in those who have obesity and T2DM 10
GLP-1 medications work by reducing appetite and slowing digestion, and, as a result, many people who use GLP-1 agonists as part of their weight-loss journey eat less
95% CI, 1.00 to 1.77) exhibited a significantly elevated risk, whereas dulaglutide did not
The results were striking: women taking GLP-1s showed a 72% improvement in natural pregnancy rates (RR: 1.72, 95% CI 1.22-2.43), meaning they were 1.72 times more likely to conceive naturally compared to the control group